Therefore, the phase III CTONG 0901 trial was conducted to compare the efficacy and safety of gefitinib with that of erlotinib in patients with metastatic NSCLC characterized by EGFR exon 19 or 21 mutations [28]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.